Andrei R. Shustov
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment 113
- Dermatology top 0.2%
- Cutaneous lymphoproliferative disorders research 33
- Immunology top 1%
- T-cell and Retrovirus Studies 36
- Oncology top 1%
- CAR-T cell therapy research 35
- Viral-associated cancers and disorders 19
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 23
-
- Histone Deacetylase Inhibitors Research 20
-
- CNS Lymphoma Diagnosis and Treatment 15
Andrei R. Shustov
154 papers receiving 5.2k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Pathology and Forensic Medicine 3.3k
- Dermatology 1.4k
- Immunology 2.0k
- Oncology 2.5k
- Genetics 790
Countries citing papers authored by Andrei R. Shustov
This map shows the geographic impact of Andrei R. Shustov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrei R. Shustov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrei R. Shustov more than expected).
Fields of papers citing papers by Andrei R. Shustov
This network shows the impact of papers produced by Andrei R. Shustov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrei R. Shustov. The network helps show where Andrei R. Shustov may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andrei R. Shustov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 4 | |
| 2 | 2021 | 60 | |
| 3 | 2021 | 33 | |
| 4 | 2020 | 9 | |
| 5 | 2019 | 5 | |
| 6 | 2019 | 67 | |
| 7 | 2018 | 1 | |
| 8 | 2018 | 88 | |
| 9 | 2017 | 3 | |
| 10 | 2017 | 3 | |
| 11 | Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Studybreakdown → | 2015 | 386 |
| 12 | 2015 | 66 | |
| 13 | 2015 | 12 | |
| 14 | 2013 | 2 | |
| 15 | Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapybreakdown → | 2012 | 485 |
| 16 | Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Studybreakdown → | 2011 | 439 |
| 17 | 2011 | 64 | |
| 18 | 2008 | 32 | |
| 19 | 2001 | 124 | |
| 20 | Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. | 1998 | 86 |
About Andrei R. Shustov
Andrei R. Shustov is a scholar working on Pathology and Forensic Medicine, Dermatology and Oncology, having authored 158 papers that have together received 5.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (113 papers), T-cell and Retrovirus Studies (36 papers), CAR-T cell therapy research (35 papers), Cutaneous lymphoproliferative disorders research (33 papers), Chronic Lymphocytic Leukemia Research (23 papers), Histone Deacetylase Inhibitors Research (20 papers), Viral-associated cancers and disorders (19 papers) and CNS Lymphoma Diagnosis and Treatment (15 papers). The work is most often cited by research in Pathology and Forensic Medicine (3.3k citations), Dermatology (1.4k citations) and Immunology (2.0k citations). Andrei R. Shustov has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Barbara Pro, Nancy L. Bartlett, Ranjana H. Advani, Michelle A. Fanale, Charles S. Via, Dana A. Kennedy, Phuong Nguyen, Tim Illidge, Steven M. Horwitz and Lauren Pinter‐Brown. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.